Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years
This cohort study found that a low baseline PSA level was associated with low long-term prostate cancer risk among men aged 45 to 70 years, supporting risk-adapted screening with extended intervals for men with low PSA levels.
Authors
- Tobias Penzkofer (ORCID: https://orcid.org/0000-0001-9591-8575)
- Ivo G. Schoots (ORCID: https://orcid.org/0000-0002-9804-0603)
- Maximilian Lindholz (ORCID: https://orcid.org/0000-0003-3690-1161)
- Charlie Alexander Hamm (ORCID: https://orcid.org/0000-0003-4104-4758)
- Georg Lukas Baumgärtner
- Martin Burchardt
- Robin Bülow
- Norbert Hosten
- Carsten O. Schmidt
- Saskia Nolte
- Henry Völzke
- Mark O. Wielpütz
- Marc Kölln
- Jean-Francois Chenot
Institutions
- Universitätsmedizin Greifswald (DE)
- Erasmus MC (NL)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.56732
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Vertex Pharmaceuticals
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Astellas Pharma
- Siemens Healthineers
- Stiftung Charité
- Berlin Institute of Health
- Astellas Pharma Global Development
- Horizon 2020 Framework Programme